Teva Could Face Damages Of $1.2 Billion For At-Risk Launch Of Generic Protonix
This article was originally published in The Pink Sheet Daily
Executive Summary
A jury finds that Pfizer's patent on the proton pump inhibitor is valid; analyst Timothy Anderson estimates that without a settlement Teva's damages could top $1 billion but thinks the actual impact will be smaller.
You may also be interested in...
Protonix Settlement Leaves Question Of How Jury Would Assess At-Risk Launch Damages
Teva and India’s Sun Pharma are to pay $2.15 billion for their at-risk launch in the U.S. of generic versions of Pfizer’s Protonix; Pfizer says figure represents lost profits and lost royalties from the three years the product faced premature generic competition.
Protonix Settlement Leaves Question Of How Jury Would Assess At-Risk Launch Damages
Teva and Sun are to pay $2.15 billion for their at-risk launch of generic versions of Pfizer’s Protonix; Pfizer says figure represents lost profits and lost royalties from the three years the product faced premature generic competition.
AstraZeneca, Korea’s Hanmi Move To Appellate Court In Nexium Patent Dispute
A recent settlement agreement at the U.S. district court level does little to resolve a battle over AstraZeneca’s second best-selling drug. Hanmi says its position is on “solid ground,” but it remains unclear if it would pursue an at-risk launch if it receives final FDA approval.